<DOC>
	<DOC>NCT02719951</DOC>
	<brief_summary>Glutamatergic transmission exploration using PET (Positron Emission Tomography) imaging in autism compared to Fragile-X Syndrome ( FXS) and Healthy Volunteers</brief_summary>
	<brief_title>Glutaminergic Transmission in Autism : Molecular Imaging Exploration</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Male Between 18 yearsold and 45 yearsold Informed, written consent obtained from patient or his representant Subject with an affiliation to French social security For autistic patient : patient with diagnosis of ASD (Autistic Spectrum Disorders) following DSMIV or DSM5 criteria with recommended tools (ADIR and/or ADOS) For FXS patient : diagnosis of FXS and confirmation of total mutation of FMR1 Contraindications to MRI Excessive use of alcohol or drug, or addiction to alcohol or drug during last 6 months Any unstable or uncontrolled disease, clinically significant Participation to an other experimental protocol with drug or irradiant exam Person under exclusion period because of previous participation to an other experimental protocol Person under temporary guardianship Forbidden treatments : any psychotropic treatment for 4 last weeks before PET exam and changing durably glutaminergic transmission directly or undirectly For healthy subjects : adult under guardianship, medical history of central nervous system disease, medical history of attention deficit hyperactivity disorder, past or present psychiatric or neurologic disorder (MINI DSMIV)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>autism</keyword>
	<keyword>fragile X syndrome (FXS)</keyword>
	<keyword>PET (Positron Emission Tomography)</keyword>
	<keyword>glutamate</keyword>
</DOC>